Laurus Labs Ltd.

NSE: LAURUSLABS | BSE: 540222 | ISIN: INE947Q01028 | Industry: Pharmaceuticals
| Expensive Performer
607.3500 4.30 (0.71%)
NSE May 19, 2025 15:58 PM
Volume: 2.2M
 

logo
Laurus Labs Ltd.
22 Dec 2020
607.35
0.71%
Sharekhan
Further, the company's foray in the lucrative biologics/biotech space through the acquisition of a majority stake in Richcore Lifesciences would be a key positive as it would create a new revenue stream. We interacted with the management of Laurus Labs Limited (Laurus) and their commentary suggests a robust growth outlook. Laurus' formulations business is gaining traction with the tender business, which accounts for around three-fourth of total formulation sales, is witnessing sturdy growth. Moreover, Laurus is expanding capacities, primarily through brownfield expansions to cater to increasing demand. The first leg of de-bottlenecking is...
KRChoksey released a Accumulate report for Laurus Labs Ltd. with a price target of 687.0 on 30 Apr, 2025.
More from Laurus Labs Ltd.
Recommended